HIVandHepatitis.com coverage of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2014) in Boston, November 7-11, 2014.
Conference highlights include new interferon-free therapy for hepatitis C -- including options for people with cirrhosis, and liver transplant recipients -- treatment for hepatitis B, and prevention and management of advanced liver disease.
HIVandHepatitis.com coverage of the 20th International AIDS Conference (AIDS 2014), July 20-25, in Melbourne, Australia.
Conference highlights include biomedical HIV prevention (PrEP and treatment-as-prevention), HIV cure research, interferon-free therapy for hepatitis C and HIV/HCV coinfection, access to treatment, and fighting stigma and criminalization of key affected populations.
In addition to the usual risk factors for hepatitis C virus (HCV) sexual transmission seen in most previous studies -- such as anal sex and having other sexually transmitted infections -- researchers in the Netherlands also saw an association with nasal and injection drug use and lower CD4 T-cell count, they reported in a poster presentation at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
The new oral hepatitis C drug sofosbuvir, either in the sofosbuvir/ ledipasvir coformulation (Harvoni) or with other direct-acting antivirals, should not be taken with the anti-arrhythmic medication amiodarone, the U.S. Food and Drug Association (FDA) and Gilead Sciences warned after several patients developed decreased heart rate (bradycardia) and 1 had a fatal heart attack when they combined these drugs.